|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2000-8-15
|
|
pubmed:abstractText |
The use of a high dose regimen of interferon-alpha-2b (IFN) has recently been demonstrated to benefit patients with resected high risk melanoma. The incidence of melanoma is rising rapidly, and the use of this regimen is becoming increasingly common. IFN has been associated with numerous psychiatric side effects.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Acetic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Amines,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Anxiety Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antimanic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclohexanecarboxylic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/gabapentin,
http://linkedlifedata.com/resource/pubmed/chemical/gamma-Aminobutyric Acid,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2000 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
89
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
356-62
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10918166-Acetic Acids,
pubmed-meshheading:10918166-Adult,
pubmed-meshheading:10918166-Amines,
pubmed-meshheading:10918166-Anti-Anxiety Agents,
pubmed-meshheading:10918166-Antimanic Agents,
pubmed-meshheading:10918166-Antineoplastic Agents,
pubmed-meshheading:10918166-Bipolar Disorder,
pubmed-meshheading:10918166-Chemotherapy, Adjuvant,
pubmed-meshheading:10918166-Cyclohexanecarboxylic Acids,
pubmed-meshheading:10918166-Depression,
pubmed-meshheading:10918166-Female,
pubmed-meshheading:10918166-Humans,
pubmed-meshheading:10918166-Interferon-alpha,
pubmed-meshheading:10918166-Male,
pubmed-meshheading:10918166-Melanoma,
pubmed-meshheading:10918166-Middle Aged,
pubmed-meshheading:10918166-Mood Disorders,
pubmed-meshheading:10918166-Prospective Studies,
pubmed-meshheading:10918166-Recombinant Proteins,
pubmed-meshheading:10918166-gamma-Aminobutyric Acid
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes.
|
|
pubmed:affiliation |
Massachusetts General Hospital, Boston 02114, USA.
|
|
pubmed:publicationType |
Journal Article,
Review,
Case Reports
|
